Atrial Fibrillation (AF)

Cardiovascular·MeSH: Atrial Fibrillation

Prevalence

1200.0 / 100K

Incidence

100.0 / 100K/yr

21 drugs in development·9 companies·18 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
multaq	Sanofi (SNY)

Phase 3(8)

Drug	Company
abelacimab	Dianthus Therapeutics, Inc. /DE/ (DNTH)
Androgen-deprivation Therapy	Crinetics Pharmaceuticals, Inc. (CRNX)
Consolidation Therapy	Crinetics Pharmaceuticals, Inc. (CRNX)
Maintenance Therapy	Crinetics Pharmaceuticals, Inc. (CRNX)
nPulse Cardiac Catheter System	Pulse Biosciences Inc Common Stock (DE) (PLSE)
nPulse Cardiac Surgical Clamp (nsPFA Cardiac Surgery System)	Pulse Biosciences Inc Common Stock (DE) (PLSE)
Re-induction Therapy	Crinetics Pharmaceuticals, Inc. (CRNX)
Rescue medications for sacituzumab tirumotecan	Merus N.V. (MRUS)

Phase 2(2)

Drug	Company
regn7508	REGENERON PHARMACEUTICALS, INC. (REGN)
regn9933	REGENERON PHARMACEUTICALS, INC. (REGN)

Phase 1(1)

Drug	Company
Rescue Medications	Merus N.V. (MRUS)

Unknown(3)

Drug	Company
CellFX nsPFA 360° Cardiac Catheter	Pulse Biosciences Inc Common Stock (DE) (PLSE)
CellFX nsPFA Cardiac Clamp	Pulse Biosciences Inc Common Stock (DE) (PLSE)
gencaro	Oruka Therapeutics, Inc. (ORKA)

N/A(1)

Drug	Company
Optimized Medical Therapy for Atrial Fibrillation	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 4(5)

Drug	Company
flecainide	CYTOKINETICS INC (CYTK)
Nicotine Replacement Therapy	Crinetics Pharmaceuticals, Inc. (CRNX)
pantoprazole	GH Research PLC (GHRS)
rebamipide	GH Research PLC (GHRS)
Sotalol or Amiodarone	CYTOKINETICS INC (CYTK)

BioSniper tracks 21 drugs in development for Atrial Fibrillation (AF) across 9 companies.

There are 18 clinical trials targeting Atrial Fibrillation (AF) tracked by BioSniper.

The estimated prevalence of Atrial Fibrillation (AF) is approximately 1200.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.